Aeterna Zentaris to Announce Top-Line Results of the ZoptEC Phase 3 Clinical Study of Zoptrex™
April 28 2017 - 4:00PM
Business Wire
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the
“Company”) will announce the top-line results of the ZoptEC Phase 3
clinical study of Zoptrex™ (zoptarelin doxorubicin) in women with
locally advanced, recurrent or metastatic endometrial cancer prior
to the commencement of trading on Monday, May 1, 2017.
Conference Call
The Company will host a conference call to discuss the results
of the ZoptEC Phase 3 clinical study of Zoptrex™ on Monday, May 1,
2017, at 8:30 AM, Eastern Time. Participants may access the
conference call by using the following number: 201-689-8029,
Confirmation 13660857.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel treatments in
oncology, endocrinology and women’s health. We are engaged in drug
development activities and in the promotion of products for others.
We recently completed Phase 3 studies of two internally developed
compounds. The focus of our business development efforts is the
acquisition of licenses to products that are relevant to our
therapeutic areas of focus. We also intend to license out certain
commercial rights of internally developed products to licensees in
non-US territories where such out-licensing would enable us to
ensure development, registration and launch of our product
candidates. Our goal is to become a growth-oriented specialty
biopharmaceutical company by pursuing successful development and
commercialization of our product portfolio, achieving successful
commercial presence and growth, while consistently delivering value
to our shareholders, employees and the medical providers and
patients who will benefit from our products. For more information,
visit www.aezsinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170428005530/en/
Aeterna Zentaris Inc.Philip A. Theodore, 843-900-3223Senior Vice
Presidentir@aezsinc.com
Aeterna Zentaris (TSX:AEZS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeterna Zentaris (TSX:AEZS)
Historical Stock Chart
From Apr 2023 to Apr 2024